Rapport Therapeutics RAPP
NASDAQ RAPP
$26.70 -2.67 (-9.07%)
As of: Oct 21, 2026 · 11:41 AM EDT

Rapport Therapeutics (RAPP) Receivables (2026)

Updated

Rapport Therapeutics (RAPP) reported Receivables of $300,000 for Q2 2026, up 417.2% from the prior quarter.

Analysis

Rapport Therapeutics (RAPP) Receivables (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,130.22 Bn 1,098.81 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 613.62 Bn 532.15 Bn 17.26 Bn 19.05 Bn
3 AbbVie 501.46 Bn 474.57 Bn 12.70 Bn 13.82 Bn
4 Merck 366.84 Bn 321.22 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 261.66 Bn 235.34 Bn 12.86 Bn 15.68 Bn
7 Amgen 235.39 Bn 190.79 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 190.66 Bn 164.86 Bn 6.22 Bn 5.06 Bn
9 Pfizer 169.57 Bn 116.22 Bn 10.94 Bn 12.49 Bn
10 Rapport Therapeutics 1.27 Bn 448.61 Mn - 300,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 300,000.00
Mar 31, 2026 58,000.00
API Access

Rapport Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=RAPP&period=max&api_key=YOUR_API_KEY